[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2017-2022 Global and Japan Conjugate Vaccine Market Analysis Report

August 2017 | 103 pages | ID: 2A9E32AD39CEN
JP Research

US$ 3,085.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global Conjugate Vaccine market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022.

Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2017, with a CAGR of xx%.

This report, with focus on top players in the global and Japan, studies the Conjugate Vaccine market's development status and future trend in the global and Japan. It splits Conjugate Vaccine market by type and by applications to fully and deeply research and reveal market profile and prospect.

The major players include
  • Bharat Biotech (India)
  • Biological E (India)
  • CSL Limited (Australia)
  • GlaxoSmithKline (U.K.)
  • Merck and Company (U.S.)
  • Neuron Biotech (U.S.)
  • Novartis AG (Switzerland)
  • Pfizer (U.S.)
  • Sanofi Pasteur (France)
Geographically, this report splits the Global market into the following regions:
  • Asia Pacific
    • Japan
      • Tokyo
      • Yokohama
      • Osaka
      • Nagoya
      • Others
    • China
    • Korea
    • India
    • Others
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Russia
    • Others
  • North America
    • United States
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Southeast Asia
    • Singapore
    • Malaysia
    • Vietnam
    • Myanmar
    • Thailand
    • Indonesia
    • Philippines
    • Others
  • Middle East & Africa
    • Saudi Arabia
    • Iran
    • UAE
    • Turkey
    • Israel
    • Egypt
    • South Africa
    • Others
On the basis of product, the Conjugate Vaccine market is primarily split into

By Disease Indication
  • Pneumococcal
  • Influenza
  • Diphtheria Tetanus Pertussis
  • Meningococcal
By Type
  • Monovalent
  • Multivalen
By Patient Stage
  • Pediatrics
  • Adult
Key Applications
  • Hospital
  • Medical Center
2017-2022 GLOBAL AND JAPAN CONJUGATE VACCINE MARKET ANALYSIS REPORT

1 CONJUGATE VACCINE OVERVIEW

1.1 Product Overview and Scope of Conjugate Vaccine
1.2 Global and Japan Conjugate Vaccine Market by Applications/End Users
  1.2.1 Japan Conjugate Vaccine Sales (K Pcs) and Market Share Comparison by Applications (2012-2017)
    1.2.1.1 Japan Conjugate Vaccine Sales (K Pcs) and Market Share by Applications (2012-2017)
    1.2.1.2 Japan Conjugate Vaccine Sales Growth Rate (%) by Applications (2012-2017)
    1.2.1.3 Market Drivers and Opportunities
  1.2.2 Japan Conjugate Vaccine Sales (K Pcs) and Market Share Comparison by Applications (2012-2017)
  1.2.3 Global Conjugate Vaccine Sales by Application (2012-2017)
    1.2.3.1 Global Conjugate Vaccine Sales (K Pcs) and Market Share by Applications (2012-2017)
    1.2.3.2 Global Conjugate Vaccine Sales Growth Rate (%) by Applications (2012-2017)
    1.2.3.3 Market Drivers and Opportunities
  1.2.4 Global Conjugate Vaccine Sales (K Pcs) and Market Share Comparison by Applications (2012-2017)
  1.2.5 Hospital
  1.2.6 Medical Center
1.3 Global and Japan Market Size (Sales and Revenue) of Conjugate Vaccine (2012-2017)
  1.3.1 Japan Market Size (Sales and Revenue) of Conjugate Vaccine (2012-2017)
    1.3.1.1 Japan Conjugate Vaccine Sales (K Pcs) and Growth Rate (%) (2012-2017)
    1.3.1.2 Japan Conjugate Vaccine Revenue (Million USD) and Growth Rate (2012-2017)
  1.3.2 Global Market Size (Sales and Revenue) of Conjugate Vaccine (2012-2017)
    1.3.2.1 Global Conjugate Vaccine Sales (K Pcs) and Growth Rate (%) (2012-2017)
    1.3.2.2 Global Conjugate Vaccine Revenue (Million USD) and Growth Rate (2012-2017)
1.4 Global and Japan Classification of Conjugate Vaccine by Disease Indication
  1.4.1 Japan Conjugate Vaccine Sales (K Pcs) and Market Share by Disease Indication (2012-2017)
  1.4.2 Global Conjugate Vaccine Sales (K Pcs) and Market Share by Disease Indication (2012-2017)
  1.4.3 Japan Conjugate Vaccine Revenue (Million USD) and Market Share by Disease Indication (2012-2017)
  1.4.4 Global Conjugate Vaccine Revenue (Million USD) and Market Share by Disease Indication (2012-2017)
  1.4.5 Japan Conjugate Vaccine Price (USD/Pcs) by Disease Indication (2012-2017)
  1.4.6 Global Conjugate Vaccine Price (USD/Pcs) by Disease Indication (2012-2017)
  1.4.7 Japan Conjugate Vaccine Sales Growth Rate (%) by Disease Indication (2012-2017)
  1.4.8 Global Conjugate Vaccine Sales Growth Rate (%) by Disease Indication (2012-2017)
  1.4.9 Pneumococcal
  1.4.10 Influenza
  1.4.11 Diphtheria Tetanus Pertussis
  1.4.12 Meningococcal
1.5 Global and Japan Classification of Conjugate Vaccine by Type
  1.5.1 Japan Conjugate Vaccine Sales (K Pcs) and Market Share by Type (2012-2017)
  1.5.2 Global Conjugate Vaccine Sales (K Pcs) and Market Share by Type (2012-2017)
  1.5.3 Japan Conjugate Vaccine Revenue (Million USD) and Market Share by Type (2012-2017)
  1.5.4 Global Conjugate Vaccine Revenue (Million USD) and Market Share by Type (2012-2017)
  1.5.5 Japan Conjugate Vaccine Price (USD/Pcs) by Type (2012-2017)
  1.5.6 Global Conjugate Vaccine Price (USD/Pcs) by Type (2012-2017)
  1.5.7 Japan Conjugate Vaccine Sales Growth Rate (%) by Type (2012-2017)
  1.5.8 Global Conjugate Vaccine Sales Growth Rate (%) by Type (2012-2017)
  1.5.9 Monovalent
  1.5.10 Multivalen
1.6 Global and Japan Classification of Conjugate Vaccine by Patient Stage
  1.6.1 Japan Conjugate Vaccine Sales (K Pcs) and Market Share by Patient Stage (2012-2017)
  1.6.2 Global Conjugate Vaccine Sales (K Pcs) and Market Share by Patient Stage (2012-2017)
  1.6.3 Japan Conjugate Vaccine Revenue (Million USD) and Market Share by Patient Stage (2012-2017)
  1.6.4 Global Conjugate Vaccine Revenue (Million USD) and Market Share by Patient Stage (2012-2017)
  1.6.5 Japan Conjugate Vaccine Price (USD/Pcs) by Patient Stage (2012-2017)
  1.6.6 Global Conjugate Vaccine Price (USD/Pcs) by Patient Stage (2012-2017)
  1.6.7 Japan Conjugate Vaccine Sales Growth Rate (%) by Patient Stage (2012-2017)
  1.6.8 Global Conjugate Vaccine Sales Growth Rate (%) by Patient Stage (2012-2017)
  1.6.9 Pediatrics
  1.6.10 Adult

2 GLOBAL AND JAPAN CONJUGATE VACCINE MARKET COMPETITION BY PLAYERS/MANUFACTURERS

2.1 Japan Conjugate Vaccine Market Competition by Players/Manufacturers
  2.1.1 Japan Conjugate Vaccine Sales and Market Share of Key Players/Manufacturers (2012-2017)
  2.1.2 Japan Conjugate Vaccine Revenue and Share by Players/Manufacturers (2012-2017)
  2.1.3 Japan Conjugate Vaccine Average Price (USD/Pcs) by Players/Manufacturers (2012-2017)
  2.1.4 Japan Conjugate Vaccine Market Competitive Situation and Trends
    2.1.4.1 Japan Conjugate Vaccine Market Concentration Rate
    2.1.4.2 Japan Conjugate Vaccine Market Share of Top 3 and Top 5 Players/Manufacturers
    2.1.4.3 Mergers & Acquisitions, Expansion in Japan Market
  2.1.5 Japan Players/Manufacturers Conjugate Vaccine Manufacturing Base Distribution, Sales Area, Product Types
2.2 Global Conjugate Vaccine Market Competition by Players/Manufacturers
  2.2.1 Global Conjugate Vaccine Sales and Market Share of Key Players/Manufacturers (2012-2017)
  2.2.2 Global Conjugate Vaccine Revenue and Share by Players/Manufacturers (2012-2017)
  2.2.3 Global Conjugate Vaccine Average Price (USD/Pcs) by Players/Manufacturers (2012-2017)
  2.2.4 Global Conjugate Vaccine Market Competitive Situation and Trends
    2.2.4.1 Global Conjugate Vaccine Market Concentration Rate
    2.2.4.2 Global Conjugate Vaccine Market Share of Top 3 and Top 5 Players/Manufacturers
    2.2.4.3 Mergers & Acquisitions, Expansion in Global Market
  2.2.5 Global Players/Manufacturers Conjugate Vaccine Manufacturing Base Distribution, Sales Area, Product Types

3 GLOBAL AND JAPAN CONJUGATE VACCINE SALES AND REVENUE BY REGIONS (2012-2017)

3.1 Asia Pacific Conjugate Vaccine Sales and Revenue by Regions (2012-2017)
  3.1.1 Japan Conjugate Vaccine Sales and Revenue (2012-2017)
    3.1.1.1 Japan Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.1.1.2 Japan Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.1.1.3 Japan Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.1.2 China Conjugate Vaccine Sales and Revenue (2012-2017)
    3.1.2.1 China Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.1.2.2 China Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.1.2.3 China Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.1.3 Korea Conjugate Vaccine Sales and Revenue (2012-2017)
    3.1.3.1 Korea Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.1.3.2 Korea Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.1.3.3 Korea Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.1.4 India Conjugate Vaccine Sales and Revenue (2012-2017)
    3.1.4.1 India Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.1.4.2 India Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.1.4.3 India Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.1.5 Others Conjugate Vaccine Sales and Revenue (2012-2017)
    3.1.5.1 Others Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.1.5.2 Others Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.1.5.3 Others Conjugate Vaccine Price (USD/Pcs)(2012-2017)
3.2 Europe Conjugate Vaccine Sales and Revenue by Regions (2012-2017)
  3.2.1 France Conjugate Vaccine Sales and Revenue (2012-2017)
    3.2.1.1 France Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.2.1.2 France Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.2.1.3 France Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.2.2 Germany Conjugate Vaccine Sales and Revenue (2012-2017)
    3.2.2.1 Germany Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.2.2.2 Germany Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.2.2.3 Germany Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.2.3 United Kingdom Conjugate Vaccine Sales and Revenue (2012-2017)
    3.2.3.1 United Kingdom Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.2.3.2 United Kingdom Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.2.3.3 United Kingdom Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.2.4 Italy Conjugate Vaccine Sales and Revenue (2012-2017)
    3.2.4.1 Italy Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.2.4.2 Italy Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.2.4.3 Italy Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.2.5 Russia Conjugate Vaccine Sales and Revenue (2012-2017)
    3.2.5.1 Russia Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.2.5.2 Russia Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.2.5.3 Russia Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.2.6 Others Conjugate Vaccine Sales and Revenue (2012-2017)
    3.2.6.1 Others Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.2.6.2 Others Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.2.6.3 Others Conjugate Vaccine Price (USD/Pcs)(2012-2017)
3.3 North America Conjugate Vaccine Sales and Revenue by Regions (2012-2017)
  3.3.1 United States Conjugate Vaccine Sales and Revenue (2012-2017)
    3.3.1.1 United States Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.3.1.2 United States Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.3.1.3 United States Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.3.2 Canada Conjugate Vaccine Sales and Revenue (2012-2017)
    3.3.2.1 Canada Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.3.2.2 Canada Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.3.2.3 Canada Conjugate Vaccine Price (USD/Pcs)(2012-2017)
3.4 Latin America Conjugate Vaccine Sales and Revenue by Regions (2012-2017)
  3.4.1 Brazil Conjugate Vaccine Sales and Revenue (2012-2017)
    3.4.1.1 Brazil Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.4.1.2 Brazil Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.4.1.3 Brazil Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.4.2 Mexico Conjugate Vaccine Sales and Revenue (2012-2017)
    3.4.2.1 Mexico Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.4.2.2 Mexico Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.4.2.3 Mexico Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.4.3 Others Conjugate Vaccine Sales and Revenue (2012-2017)
    3.4.3.1 Others Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.4.3.2 Others Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.4.3.3 Others Conjugate Vaccine Price (USD/Pcs)(2012-2017)
3.5 Southeast Asia Conjugate Vaccine Sales and Revenue by Regions (2012-2017)
  3.5.1 Singapore Conjugate Vaccine Sales and Revenue (2012-2017)
    3.5.1.1 Singapore Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.5.1.2 Singapore Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.5.1.3 Singapore Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.5.2 Malaysia Conjugate Vaccine Sales and Revenue (2012-2017)
    3.5.2.1 Malaysia Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.5.2.2 Malaysia Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.5.2.3 Malaysia Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.5.3 Vietnam Conjugate Vaccine Sales and Revenue (2012-2017)
    3.5.3.1 Vietnam Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.5.3.2 Vietnam Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.5.3.3 Vietnam Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.5.4 Myanmar Conjugate Vaccine Sales and Revenue (2012-2017)
    3.5.4.1 Myanmar Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.5.4.2 Myanmar Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.5.4.3 Myanmar Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.5.5 Thailand Conjugate Vaccine Sales and Revenue (2012-2017)
    3.5.5.1 Thailand Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.5.5.2 Thailand Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.5.5.3 Thailand Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.5.6 Indonesia Conjugate Vaccine Sales and Revenue (2012-2017)
    3.5.6.1 Indonesia Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.5.6.2 Indonesia Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.5.6.3 Indonesia Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.5.7 Philippines Conjugate Vaccine Sales and Revenue (2012-2017)
    3.5.7.1 Philippines Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.5.7.2 Philippines Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.5.7.3 Philippines Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.5.8 Others Conjugate Vaccine Sales and Revenue (2012-2017)
    3.5.8.1 Others Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.5.8.2 Others Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.5.8.3 Others Conjugate Vaccine Price (USD/Pcs)(2012-2017)
3.6 Middle East & Africa Conjugate Vaccine Sales and Revenue by Regions (2012-2017)
  3.6.1 Saudi Arabia Conjugate Vaccine Sales and Revenue (2012-2017)
    3.6.1.1 Saudi Arabia Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.6.1.2 Saudi Arabia Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.6.1.3 Saudi Arabia Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.6.2 Iran Conjugate Vaccine Sales and Revenue (2012-2017)
    3.6.2.1 Iran Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.6.2.2 Iran Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.6.2.3 Iran Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.6.3 UAE Conjugate Vaccine Sales and Revenue (2012-2017)
    3.6.3.1 UAE Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.6.3.2 UAE Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.6.3.3 UAE Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.6.4 Turkey Conjugate Vaccine Sales and Revenue (2012-2017)
    3.6.4.1 Turkey Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.6.4.2 Turkey Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.6.4.3 Turkey Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.6.5 Israel Conjugate Vaccine Sales and Revenue (2012-2017)
    3.6.5.1 Israel Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.6.5.2 Israel Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.6.5.3 Israel Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.6.6 Egypt Conjugate Vaccine Sales and Revenue (2012-2017)
    3.6.6.1 Egypt Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.6.6.2 Egypt Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.6.6.3 Egypt Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.6.7 South Africa Conjugate Vaccine Sales and Revenue (2012-2017)
    3.6.7.1 South Africa Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.6.7.2 South Africa Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.6.7.3 South Africa Conjugate Vaccine Price (USD/Pcs)(2012-2017)
  3.6.8 Others Conjugate Vaccine Sales and Revenue (2012-2017)
    3.6.8.1 Others Conjugate Vaccine Sales (K Pcs) and Market Share (2012-2017)
    3.6.8.2 Others Conjugate Vaccine Revenue (Million USD) and Market Share (2012-2017)
    3.6.8.3 Others Conjugate Vaccine Price (USD/Pcs)(2012-2017)

4 GLOBAL AND JAPAN CONJUGATE VACCINE PLAYERS/MANUFACTURERS PROFILES AND SALES DATA

4.1 Bharat Biotech (India)
  4.1.1 Company Basic Information, Manufacturing Base and Competitors
  4.1.2 Conjugate Vaccine Product Category, Application and Specification
    4.1.2.1 Product A
    4.1.2.2 Product B
  4.1.3 Bharat Biotech (India) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.1.4 Main Business/Business Overview
4.2 Biological E (India)
  4.2.1 Company Basic Information, Manufacturing Base and Competitors
  4.2.2 Conjugate Vaccine Product Category, Application and Specification
    4.2.2.1 Product A
    4.2.2.2 Product B
  4.2.3 Biological E (India) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.2.4 Main Business/Business Overview
4.3 CSL Limited (Australia)
  4.3.1 Company Basic Information, Manufacturing Base and Competitors
  4.3.2 Conjugate Vaccine Product Category, Application and Specification
    4.3.2.1 Product A
    4.3.2.2 Product B
  4.3.3 CSL Limited (Australia) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.3.4 Main Business/Business Overview
4.4 GlaxoSmithKline (U.K.)
  4.4.1 Company Basic Information, Manufacturing Base and Competitors
  4.4.2 Conjugate Vaccine Product Category, Application and Specification
    4.4.2.1 Product A
    4.4.2.2 Product B
  4.4.3 GlaxoSmithKline (U.K.) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.4.4 Main Business/Business Overview
4.5 Merck and Company (U.S.)
  4.5.1 Company Basic Information, Manufacturing Base and Competitors
  4.5.2 Conjugate Vaccine Product Category, Application and Specification
    4.5.2.1 Product A
    4.5.2.2 Product B
  4.5.3 Merck and Company (U.S.) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.5.4 Main Business/Business Overview
4.6 Neuron Biotech (U.S.)
  4.6.1 Company Basic Information, Manufacturing Base and Competitors
  4.6.2 Conjugate Vaccine Product Category, Application and Specification
    4.6.2.1 Product A
    4.6.2.2 Product B
  4.6.3 Neuron Biotech (U.S.) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.6.4 Main Business/Business Overview
4.7 Novartis AG (Switzerland)
  4.7.1 Company Basic Information, Manufacturing Base and Competitors
  4.7.2 Conjugate Vaccine Product Category, Application and Specification
    4.7.2.1 Product A
    4.7.2.2 Product B
  4.7.3 Novartis AG (Switzerland) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.7.4 Main Business/Business Overview
4.8 Pfizer (U.S.)
  4.8.1 Company Basic Information, Manufacturing Base and Competitors
  4.8.2 Conjugate Vaccine Product Category, Application and Specification
    4.8.2.1 Product A
    4.8.2.2 Product B
  4.8.3 Pfizer (U.S.) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.8.4 Main Business/Business Overview
4.9 Sanofi Pasteur (France)
  4.9.1 Company Basic Information, Manufacturing Base and Competitors
  4.9.2 Conjugate Vaccine Product Category, Application and Specification
    4.9.2.1 Product A
    4.9.2.2 Product B
  4.9.3 Sanofi Pasteur (France) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
  4.9.4 Main Business/Business Overview

5 CONJUGATE VACCINE MANUFACTURING COST ANALYSIS

5.1 Conjugate Vaccine Key Raw Materials Analysis
  5.1.1 Key Raw Materials
  5.1.2 Price Trend of Key Raw Materials
  5.1.3 Key Suppliers of Raw Materials
  5.1.4 Market Concentration Rate of Raw Materials
5.2 Proportion of Manufacturing Cost Structure
  5.2.1 Raw Materials
  5.2.2 Labor Cost
  5.2.3 Manufacturing Expenses
5.3 Manufacturing Process Analysis of Conjugate Vaccine

6 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

6.1 Conjugate Vaccine Industrial Chain Analysis
6.2 Upstream Raw Materials Sourcing
6.3 Raw Materials Sources of Conjugate Vaccine Major Players/Manufacturers in 2016
6.4 Downstream Buyers

7 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

7.1 Marketing Channel
  7.1.1 Direct Marketing
  7.1.2 Indirect Marketing
  7.1.3 Marketing Channel Development Trend
7.2 Market Positioning
  7.2.1 Pricing Strategy
  7.2.2 Brand Strategy
  7.2.3 Target Client
7.3 Distributors/Traders List

8 MARKET EFFECT FACTORS ANALYSIS

8.1 Technology Progress/Risk
  8.1.1 Substitutes Threat
  8.1.2 Technology Progress in Related Industry
8.2 Consumer Needs/Customer Preference Change
8.3 Economic/Political Environmental Change

9 GLOBAL AND JAPAN CONJUGATE VACCINE MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

9.1 Global and Japan Conjugate Vaccine Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
9.2 Global and Japan Conjugate Vaccine Sales (K Pcs) Forecast by Type (2017-2022)
  9.2.1 by Disease Indication
  9.2.2 by Type
  9.2.3 by Patient Stage
9.3 Global and Japan Conjugate Vaccine Sales (K Pcs) Forecast by Application (2017-2022)
9.4 Global and Japan Conjugate Vaccine Sales (K Pcs) Forecast by Regions (2017-2022)

10 RESEARCH FINDINGS AND CONCLUSION

11 METHODOLOGY AND DATA SOURCE

11.1 Methodology/Research Approach
  11.1.1 Research Programs/Design
  11.1.2 Market Size Estimation
  11.1.3 Market Breakdown and Data Triangulation
11.2 Data Source
  11.2.1 Secondary Sources
  11.2.2 Primary Sources
11.3 Disclaimer
11.4 Author List
LIST OF TABLES AND FIGURES

Figure Product Picture of Conjugate Vaccine
Table Japan Conjugate Vaccine Sales (Million Units) Comparison by Applications (2012-2017)
Figure Japan Sales Market Share (%) of Conjugate Vaccine by Applications in 2016
Table Global Conjugate Vaccine Sales (Million Units) Comparison by Applications (2012-2017)
Figure Global Sales Market Share (%) of Conjugate Vaccine by Applications in 2016
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Medical Center Examples
Table Key Downstream Customer in Medical Center
Figure Pneumococcal Product Picture
Figure Influenza Product Picture
Figure Diphtheria Tetanus Pertussis Product Picture
Figure Meningococcal Product Picture
Figure Monovalent Product Picture
Figure Multivalen Product Picture
Figure Pediatrics Product Picture
Figure Adult Product Picture
Table Bharat Biotech (India) Basic Information List
Table Bharat Biotech (India) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table Bharat Biotech (India) Conjugate Vaccine Sales Growth Rate (%)(2012-2017)
Table Bharat Biotech (India) Conjugate Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure Bharat Biotech (India) Conjugate Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table Biological E (India) Basic Information List
Table Biological E (India) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table Biological E (India) Conjugate Vaccine Sales Growth Rate (%)(2012-2017)
Table Biological E (India) Conjugate Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure Biological E (India) Conjugate Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table CSL Limited (Australia) Basic Information List
Table CSL Limited (Australia) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table CSL Limited (Australia) Conjugate Vaccine Sales Growth Rate (%)(2012-2017)
Table CSL Limited (Australia) Conjugate Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure CSL Limited (Australia) Conjugate Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table GlaxoSmithKline (U.K.) Basic Information List
Table GlaxoSmithKline (U.K.) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table GlaxoSmithKline (U.K.) Conjugate Vaccine Sales Growth Rate (%)(2012-2017)
Table GlaxoSmithKline (U.K.) Conjugate Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure GlaxoSmithKline (U.K.) Conjugate Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table Merck and Company (U.S.) Basic Information List
Table Merck and Company (U.S.) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table Merck and Company (U.S.) Conjugate Vaccine Sales Growth Rate (%)(2012-2017)
Table Merck and Company (U.S.) Conjugate Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure Merck and Company (U.S.) Conjugate Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table Neuron Biotech (U.S.) Basic Information List
Table Neuron Biotech (U.S.) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table Neuron Biotech (U.S.) Conjugate Vaccine Sales Growth Rate (%)(2012-2017)
Table Neuron Biotech (U.S.) Conjugate Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure Neuron Biotech (U.S.) Conjugate Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table Novartis AG (Switzerland) Basic Information List
Table Novartis AG (Switzerland) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table Novartis AG (Switzerland) Conjugate Vaccine Sales Growth Rate (%)(2012-2017)
Table Novartis AG (Switzerland) Conjugate Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure Novartis AG (Switzerland) Conjugate Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table Pfizer (U.S.) Basic Information List
Table Pfizer (U.S.) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table Pfizer (U.S.) Conjugate Vaccine Sales Growth Rate (%)(2012-2017)
Table Pfizer (U.S.) Conjugate Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure Pfizer (U.S.) Conjugate Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table Sanofi Pasteur (France) Basic Information List
Table Sanofi Pasteur (France) Conjugate Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
Table Sanofi Pasteur (France) Conjugate Vaccine Sales Growth Rate (%)(2012-2017)
Table Sanofi Pasteur (France) Conjugate Vaccine Sales Market Share (%) in Japan (2012-2017)
Figure Sanofi Pasteur (France) Conjugate Vaccine Revenue Market Share (%) in Japan (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Conjugate Vaccine
Figure Manufacturing Process Analysis of Conjugate Vaccine
Figure Conjugate Vaccine Industrial Chain Analysis
Table Raw Materials Sources of Conjugate Vaccine Major Players/Manufacturers in 2016
Table Major Buyers of Conjugate Vaccine
Table Distributors/Traders List
Figure Japan Conjugate Vaccine Sales (K Pcs) and Growth Rate (%) Forecast (2017-2022)
Figure Japan Conjugate Vaccine Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure Japan Conjugate Vaccine Price (USD/Pcs) Trend Forecast (2017-2022)
Figure Global Conjugate Vaccine Sales (K Pcs) and Growth Rate (%) Forecast (2017-2022)
Figure Global Conjugate Vaccine Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure Global Conjugate Vaccine Price (USD/Pcs) Trend Forecast (2017-2022)
Table Japan Conjugate Vaccine Sales (K Pcs) Forecast by Type (2017-2022)
Table Global Conjugate Vaccine Sales (K Pcs) Forecast by Type (2017-2022)
Figure Japan Conjugate Vaccine Sales (K Pcs) Forecast by Type (2017-2022)
Figure Global Conjugate Vaccine Sales (K Pcs) Forecast by Type (2017-2022)
Figure Japan Conjugate Vaccine Sales Volume Market Share Forecast by Type in 2017
Figure Global Conjugate Vaccine Sales Volume Market Share Forecast by Type in 2017
Table Japan Conjugate Vaccine Sales (K Pcs) Forecast by Application (2017-2022)
Figure Japan Conjugate Vaccine Sales Volume Market Share Forecast by Application (2017-2022)
Figure Japan Conjugate Vaccine Sales Volume Market Share Forecast by Application in 2017
Table Global Conjugate Vaccine Sales (K Pcs) Forecast by Application (2017-2022)
Figure Global Conjugate Vaccine Sales Volume Market Share Forecast by Application (2017-2022)
Figure Global Conjugate Vaccine Sales Volume Market Share Forecast by Application in 2017
Table Japan Conjugate Vaccine Sales (K Pcs) Forecast by Regions (2017-2022)
Table Japan Conjugate Vaccine Sales Volume Share Forecast by Regions (2017-2022)
Figure Japan Conjugate Vaccine Sales Volume Share Forecast by Regions (2017-2022)
Table Global Conjugate Vaccine Sales (K Pcs) Forecast by Regions (2017-2022)
Table Global Conjugate Vaccine Sales Volume Share Forecast by Regions (2017-2022)
Figure Global Conjugate Vaccine Sales Volume Share Forecast by Regions (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources


More Publications